PharmiNews

The Directory of Pharma Companies and News

Merck

Category:
Category:

Merck News

DateNews
2016-06-27Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Can...
2016-06-24Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
2016-06-20Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cil...
2016-06-16Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
2016-06-16Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy a...
2016-06-15Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe ...
2016-06-13Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority ...
2016-06-11Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primar...
2016-06-09Merck to Acquire Afferent Pharmaceuticals
2016-06-09Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA™ (bezlotoxumab), an Investigational Agent for Prevention ...
2016-06-06KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Per...
2016-06-06Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of...
2016-06-05New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-...
2016-06-05New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch ...
2016-06-04New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Su...
2016-06-04New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cel...
2016-06-01Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
2016-05-27Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
2016-05-24Merck Announces Third-Quarter 2016 Dividend
2016-05-23Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Acc...
2016-05-23Merck Announces FDA Accepts Samsung Bioepis’ Biologics License Application (BLA) for SB2 (Infliximab), an Investigationa...
2016-05-18New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Dat...
2016-05-16New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and...
2016-05-12Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of ...
2016-05-05Merck Announces First-Quarter 2016 Financial Results
2016-05-04Merck to Present at the Deutsche Bank 41st Annual Health Care Conference
2016-04-28Christina Applegate and Merck Urge Insomnia Sufferers to Learn “Why They’re So Awake”
2016-04-19Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System
2016-04-19Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meet...
2016-04-16Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Popu...
2016-04-14Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir ...
2016-04-13FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic H...
2016-04-12Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy I...
2016-04-08Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
2016-04-07Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016
2016-04-06Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meet...
2016-04-01Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency
2016-03-30Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver Congress...
2016-03-24Merck Foundation Awards Grant to American Cancer Society for Program to Improve Access to High-Quality Cancer Care in Un...
2016-03-22MSD Animal Health Receives Positive Final Opinion from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On for ...
2016-03-09Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening Treatment Access for Veterans with Chronic He...
2016-03-08Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Opera...
2016-03-07FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell L...
2016-03-07Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire
2016-03-04Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness ...
2016-02-23Merck Announces Second-Quarter 2016 Dividend
2016-02-22Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivo...
2016-02-15Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin...
2016-02-11New Pet Diabetes Tracker from Merck Animal Health Helps Owners of Diabetic Pets Manage the Disease
2016-02-04FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic ...
2016-02-03Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
2016-01-28Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Pat...
2016-01-28Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genot...
2016-01-27Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Preve...
2016-01-19Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cance...
2016-01-15Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
2016-01-11Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
2016-01-08Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
2016-01-05Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3
2016-01-04Merck to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
2015-12-23World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing
2015-12-19Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patient...
2015-12-18Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepat...
2015-12-18FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melan...
2015-12-17Merck’s BRIDION® (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and...
2015-12-15FDA Approves Expanded Age Indication for GARDASIL® 9 in Males
2015-12-14Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
2015-12-10Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® (pembrolizumab) Combination Trial
2015-12-08Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
2015-12-07Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea
2015-12-07Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab...
2015-12-04Amgen and Merck Announce Cancer Immunotherapy Collaboration for Patients with Non-Hodgkin Lymphoma
2015-11-21Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investiga...
2015-11-20Merck Animal Health Pioneers H3N2 Canine Influenza Vaccine
2015-11-19Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
2015-11-17New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at...
2015-11-16Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis...
2015-11-14Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis...
2015-11-14Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbas...
2015-11-13Merck Provides Update on REVEAL Outcomes Study
2015-11-12Merck Animal Health to Acquire Harrisvaccines
2015-11-12Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
2015-11-06Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 ...
2015-11-06Merck Statement on FDA Advisory Committee Meeting for BRIDION® (sugammadex), Investigational Agent for the Reversal of N...
2015-11-05Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
2015-11-03GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
2015-11-02Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in ...
2015-10-28KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
2015-10-27Merck Announces Third-Quarter 2015 Financial Results
2015-10-26Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously T...
2015-10-22MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pem...
2015-10-20Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 20...
2015-10-13Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat wit...
2015-10-09KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE...
2015-10-05Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Trea...
2015-10-05Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with ...
2015-10-02FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tu...
2015-10-01Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
2015-09-29International Coalition Urges Final Push to Eliminate River Blindness from the Americas
2015-09-28Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®
2015-09-28MARIZEV® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
2015-09-27New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented ...
2015-09-26New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
2015-09-25Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27
2015-09-21Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at Eu...
2015-09-20Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Re...
2015-09-18Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
2015-09-17Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
2015-09-16Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitag...
2015-09-16Merck to Participate at the Morgan Stanley Global Healthcare Conference
2015-09-16Merck Highlights Its Commitment to Infectious Disease with 40 Presentations of Data at ICAAC/ICC 2015
2015-09-10Merck Publishes 2014 Global Corporate Responsibility Report
2015-09-08Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea
2015-09-02FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents
2015-09-01New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
2015-08-20New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Saf...
2015-08-18Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Require...
2015-08-13Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
2015-08-10Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies with Merck’s KEYTRUDA®...
2015-07-31In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
2015-07-28Merck Announces Second-Quarter 2015 Financial Results
2015-07-28Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
2015-07-28Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Invest...
2015-07-28Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
2015-07-27Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA™ (Ceftolozane and Tazobactam)
2015-07-23Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an...
2015-07-22European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-tr...
2015-07-22Merck Announces Fourth-Quarter 2015 Dividend
2015-07-21Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS
2015-07-07Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Pr...
2015-06-29Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoi...
2015-06-26Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
2015-06-17Merck Manual and MSD Manual Launch Global Medical Knowledge 2020 to Provide Free Access to Credible Medical Information ...
2015-06-11Merck Launches New Program That Encourages Women to “Rule the Real Talk” and Prioritize Their Sexual Health
2015-06-10Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and...
2015-06-08TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabet...
2015-06-03Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journ...
2015-06-01Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
2015-06-01Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now...
2015-06-01FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, ...
2015-05-30TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA® (pembrolizumab)
2015-05-29Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with K...
2015-05-29New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients wit...
2015-05-29First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembroli...
2015-05-28Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use...
2015-05-28Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combinati...
2015-05-26Merck Announces Third-Quarter 2015 Dividend
2015-05-22Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
2015-05-18Merck to Present at the UBS Global Healthcare Conference
2015-05-132015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Progr...
2015-05-07Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
2015-04-28Merck Announces First-Quarter 2015 Financial Results
2015-04-27Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The La...
2015-04-27Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
2015-04-25Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevi...
2015-04-24Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across B...
2015-04-23Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Pati...
2015-04-22Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goa...
2015-04-21Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th...
2015-04-20TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Sol...
2015-04-19KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Over...
2015-04-19Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting...
2015-04-19Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab...
2015-04-19Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma...
2015-04-14Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
2015-04-09Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-...
2015-04-08Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 The...
2015-04-08Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations...
2015-04-06Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
2015-03-31Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizu...
2015-03-27Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
2015-03-26Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Ris...
2015-03-24Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Sto...
2015-03-24Merck Announces New $10 Billion Share Repurchase Program
2015-03-18New Data Investigating Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be P...
2015-03-16New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Rec...
2015-03-13Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
2015-03-10Merck to Present at the Barclays Global Healthcare Conference
2015-03-10KEYTRUDA® (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Sche...
2015-03-05Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
2015-03-05Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Red...
2015-03-04Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK ...
2015-03-04Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK ...
2015-03-02Merck to Present at the 35th Annual Cowen Health Care Conference
2015-02-26Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females ...
2015-02-25New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) t...
2015-02-24Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir i...
2015-02-24Merck Announces Second-Quarter 2015 Dividend
2015-02-23NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
2015-02-23Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist’s 2...
2015-02-05Merck Prices $8.0 Billion Debt Offering
2015-02-04Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results
2015-02-03Merck’s Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in t...
2015-01-26Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid phosphate)
2015-01-22Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist’s 2.50% Conve...
2015-01-21Merck Completes Tender Offer to Acquire Cubist
2015-01-13Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
2015-01-12Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at ...
2015-01-09Merck to Present at the 33rd Annual J.P. Morgan Healthcare Conference
2015-01-05Merck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4
2014-12-19Merck Begins Tender Offer to Acquire Cubist
2014-12-18Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid ...
2014-12-11FDA Approves Merck's HPV Vaccine, GARDASIL®9, to Prevent Cancers and Other Diseases Caused by Nine HPV types – Including...
2014-12-10Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breas...
2014-12-10International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA ...
2014-12-10Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Pub...
2014-12-09Merck Statement Regarding CUBICIN Patent Litigation
2014-12-08Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
2014-12-06Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Pre...
2014-11-25Merck Announces Increased Quarterly Dividend
2014-11-24Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
2014-11-24Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Inves...
2014-11-24Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
2014-11-17Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific...
2014-11-17VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Pre...
2014-11-16Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients w...
2014-11-11Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Geno...
2014-11-09Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combin...
2014-11-06New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared...
2014-11-05Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
2014-11-03Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive ...
2014-10-27Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2014-10-27Merck Announces Third-Quarter 2014 Financial Results
2014-10-20US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexav...
2014-10-15Merck Announces Final Results of Tender Offers for Eight Series of Notes
2014-10-14Merck Announces Pricing of Tender Offers for Eight Series of Notes
2014-10-08Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (M...
2014-10-06Merck Announces Tender Offers for Eight Series of Notes
2014-10-06Merck Prices EUR 2.5 Billion Debt Offering
2014-10-06Merck Announces Proposed Public Debt Offering
2014-10-03Merck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness
2014-10-01Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion
2014-09-29Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients wit...
2014-05-06Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion
2013-09-25OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women, Now Available Nationwide
1970-01-01Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
1970-01-01Mundipharma receives Positive CHMP Opinion for \u003cem\u003eTargin\u003c/em\u003e\u003csup\u003e®\u003c/sup\u003e (oxyc... (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.